New Roles of Artemisinins in Atherosclerosis Progression
Phytotherapy Research · 2025-04 · 39 (4) · 1847-1857
DOI: 10.1002/ptr.8483 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Phytotherapy Research, online erschienen am 08.04.2025. Verfasst von Hamidreza Majidiani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran. Hauptthemen laut MEDLINE: Atherosclerosis, Artemisinins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
Artemisinin is a natural compound derived from the Chinese plant Artemisia annua , which was officially approved by the FDA for its antimalarial effects. In recent years, a growing body of studies has shown the novel function of artemisinin in atherosclerosis therapy. In vivo studies have shown that artemisinin can inhibit the progression of atherosclerosis plaque. In the present review, the evidence showing the inhibitory effects of artemisinin on the progression of atherosclerosis plaque and its underlying mechanisms is discussed. Mechanistically, artemisinin and its derivatives act by modulating various atherosclerosis‐mediating risk factors, including hyperlipidemia, inflammation, oxidative stress, and malfunctioning vascular smooth muscle cells (VSMCs). Notably, artesunate, but not artemisinin, can attenuate the plasma levels of TG, TC, VLDL‐C, and LDL‐c, along with a substantial decline in arterial lipid deposition through enhancing the LDPL activity via inducing the KFL2/NRF2/TCF7L2 axis. Artemisinin was found to ameliorate the atherosclerosis plaque inflammation by reducing monocyte adhesion and subsequent transmigration to the intima, via inhibiting the expression of ICAM‐1 and VCAM‐1, diminishing NLRP3 inflammasome activation, and reducing the expression of inflammatory factors such as IL‐1β, IL‐18, TNF‐α, MCP‐1, and TGF‐β1 mechanistically and mainly via suppressing the by NF‐κB activity. Artemisinin could exert antioxidant effects through activating the PI3K/Akt/eNOS signaling pathway and suppressing the ROS‐mediated NF‐κB signal pathway. Artemisinin could also improve the VSMC function in the atherosclerosis plaque. These findings can suggest artemisinin as a new therapeutic agent for treating atherosclerosis; however, future clinical trials are warranted to validate its therapeutic efficiency in patients with atherosclerosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.
- Department of Medical Biotechnology, School of Medicine, Neyshabur University of Medical Sciences, Faculty of Medicine,Neyshabur University of Medical Sciences, Neyshabur, Iran.
ORCID-Profile: Amir Abbas Momtazi-Borojeni
Zitieren
APA
Majidiani, H., Musavi, M., & Momtazi-Borojeni, A. A. (2025). New Roles of Artemisinins in Atherosclerosis Progression. Phytotherapy Research, 39(4), 1847-1857. https://doi.org/10.1002/ptr.8483
Vancouver
Majidiani H, Musavi M, Momtazi-Borojeni AA. New Roles of Artemisinins in Atherosclerosis Progression. Phytotherapy Research. 2025;39(4):1847-1857. doi:10.1002/ptr.8483
BibTeX
@article{Majidiani2025,
author = {Majidiani, Hamidreza and Musavi, Maryam and Momtazi-Borojeni, Amir Abbas},
title = {New Roles of Artemisinins in Atherosclerosis Progression},
journal = {Phytotherapy Research},
year = {2025},
volume = {39},
number = {4},
pages = {1847--1857},
doi = {10.1002/ptr.8483}
}
EUVIMED